Current aspects of salivary gland tumors – a systematic review of the literature

Aktuelle Aspekte der Speicheldrüsentumore – eine systematische Recherche der Literatur

Abstract

Objectives: This study provides an up-to-date overview of the distribution of salivary gland tumors in relation to sex, land of treatment, localization of the tumor in the mouths, and benign/malignant disease of this type of tumor. We hypothesized that the distribution of patients with salivary gland tumors could vary according to country, gender, age and tumor specificity. In addition there is a comparison of the primary classification of salivary gland tumors from 1981 and the recent classification from 2005.

Materials and methods: Data from the Medline database PubMed.gov and supplementary sources were used to conduct a systematic literature search. For this purpose, data from different studies were independently collected using a previously designed questionnaire.

Results: The first section analyzes the general features of the relevant salivary gland tumors from 141 studies involving a total of 25,826 patients across 30 different countries in terms of gender and the occurrence of benign/malignant salivary gland tumors. These data were summarized and presented.

Conclusion: This review offers an insight into the dramatic local differences with regard to salivary gland tumor occurrence as a stepping stone to further classify such data in order to derive effective therapy options, prognosis and widen the general understanding of the subject.

Keywords: salivary gland tumors, pleomorphic adenoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma

Zusammenfassung

Ziel: Unser Review gibt eine aktuelle Übersicht über das Vorkommen der Speicheldrüsentumore. Näher dargelegt wurde dabei die divergierende Verteilung dieser Tumore bezogen auf Alter, Gender, anatomische Lokalisationen und spezifische geographische Ländereinteilungen. Ebenfalls visualisiert wurden die unterschiedlich auftretenden Entitäten bezogen auf Malignität und Benignität.

Unsere Ausgangshypothese war, dass in verschiedenen Ländern die Verteilung der Tumorentitäten sowie die weiteren Charakteristika der Tumore (z.B. Alter und Gender der betroffenen Patienten, anatomische Lokalisation, Auftrittshäufigkeiten verschiedener Entitäten) variieren.

Zusätzlich gibt unser Review eine Übersicht über die Veränderung der Tumorklassifikationen seit 1981 bis 2005.

Material und Methoden: Für die systematische Literaturrecherche wurde die Datenbank PubMed.gov genutzt. Es wurde ein Fragenkatalog erstellt und Studien aus verschiedenen Ländern aufgenommen und analysiert.

Ergebnisse: Durch das erste Auswahlverfahren wurden 141 Studien aus über 30 Ländern selektiert. Die somit erfasste Patientenkohorte betrug 25.826. Die Daten aus diesen Studien wurden bezüglich der
verschiedenen Länder, Alter, Gender und dem Auftreten unterschiedlicher benigner und maligner Entitäten zusammengesetzt und analysiert. 

**Schlussfolgerung:** Dieses Review verdeutlicht die starken lokalen Unterschiede im Auftreten der Speicheldrüsentumoren. Unsere gesammelten Daten sollten als Grundstein für weitere Forschungen bezogen auf Therapieoptionen, Prognosen und Vorhersagen zu dem Auftreten von Speicheldrüsentumoren genommen werden.

**Schlüsselwörter:** Speicheldrüsentumore, pleomorphes Adenom, Adenoidzystisches Karzinom, Mukoepidermoidkarzinom, Azinuszellkarzinom

### Introduction

Salivary gland tumors are a rare phenomenon. This heterogeneous group of pathologies encompasses approximately 3–5% of head and neck carcinomas, and only 0.5% of all malignant tumors match these types [1]. The incidence of all salivary gland tumors varies between 0.3 to 4 per 100,000, population, with the highest identified among the Inuit [2], [3].

The results of current studies focus on isolated characteristics of the salivary gland tumors (e.g., age and gender, therapy, localization, etc.) as opposed to a holistic view of salivary gland tumors, and therefore, they need to be summarized and visualized to be easily comparable in terms of the epidemiology, therapy, and prognosis. Some different reviews concerning salivary gland tumors have been published in the last two centuries [1], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18] most of which discuss the entities or diagnostic or prognostic aspects and principal therapeutic strategies in detail. However, there is no research article that described an overview of the gender-specific distribution as well as country-specific differences for those tumors. Therefore, the purpose of this actual article is to present an up-to-date overview of the characteristics of salivary gland tumors through a literature review. This overview will detail the epidemiologic, gender, benign/malign and country-specific distributions of this tumor entities. Moreover, this work presents an inventory of the current state with regard to salivary gland tumors in general.

### Material and methods

#### Study selection criteria

The literature search was carried out until January 2018, and includes articles dating back as far as 1981. The databases were searched for relevant studies using the key words “salivary gland tumors”, “pleomorphic adenoma”, “adenoid cystic carcinoma”, “mucoepidermoid carcinoma” and “acinic cell carcinoma”. As support, 3 textbooks and 1 medical doctoral thesis were used to complement the article. All the used sources are freely accessible.

Studies eligible for inclusion in this analysis had to meet the following criteria: recent publications (between 1981 and 2018), statistically evaluable, multiple salivary gland tumor types, various geographic and anatomic locations, therapy analysis, prognosis with a focus on survival (disease-free survival, overall survival, relapse time, among others), case studies, clinico-pathological studies in hospitals, retrospective cohort studies in patients with salivary gland tumors and reviews.

Two reviewers (TMG and AWE) independently carried out the study selection, data extraction, and quality assessment. The reviewers independently screened all records (titles and abstract) that were identified by the search strategy to select potentially eligible publications. Care has being taken to discard duplicated content, outdated and unrelated studies. Country-based statistics were derived from individual clinic data with a significant amount of patients only.

### Results

#### Epidemiological data

Patient ages ranged from 2.5 to 92 years [5], [19], even though some studies focused on occurrences in children. The mean age ranged from 41.9 to 43 years [19], [20], correlating with a peak in the fifth decade of life [21]. Benign tumors were more likely in younger patients aged 35.0±17.2 years and malignant tumors in older patients aged 48.8±18.2 [22].

---

**GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW 2019, Vol. 8, ISSN 2193-8091**

2/8
Depending on the country of origin, the distributions of salivary gland tumors differed between men and women. In China, the distribution of men/women was 1:0.9 [23], and in Nigeria it was 1:1.8 [19]. No special data were found for all salivary gland tumors, or specifically for tumors of minor salivary glands in Germany. Table 1 shows the detailed gender distribution of different countries.

**Anatomical localization**

Between 60 and 84.2% of all tumors were to be found in the parotid glands [6], [20], but only 16% were in the submandibular glands. Tumors of the sublingual gland were rare, but all were malignant according to Luksic et al. [24]. Malignant tumors are generally less common than benign tumors in the large salivary glands [6]. Minor salivary gland tumors were found in 24 to 39.3% of cases [19], [20]. The palate was the most common site of minor salivary gland tumors in 33.3 to 67% of cases [21], [25], followed by the upper lip and buccal mucosa [26]. A larger proportion of benign tumors were found in the palate of females (75.00%) compared with male patients (64.00%) [7].

**Diagnostic approaches**

Preoperative diagnostics are mainly based on imaging methods and pathological findings, especially fine-needle aspiration cytology (FNAC) [2]. Ultrasound, magnetic resonance imaging (MRI) and contrast-enhanced computed tomography (CT) are the most commonly used imaging modalities to evaluate salivary gland lesions [27]. Ultrasound remains the basic diagnostic imaging procedure, especially when occurring in parotid glands [2]. As a low cost, non-invasive modality, ultrasound provides excellent localization of the tumor in the gland and enables differentiation from the cystic mass [2]. For lesions of the minor and sublingual salivary glands of the deep parotid lobe or of malignant neoplasia with suspected perineural invasion or bone infiltration, MRI is mandatory to evaluate the tumor extent, local invasion and perineural spread [2].

CT should be an alternative modality when MRI is not available. Certain carcinomas (for example, mucoepidermoid carcinoma, adenoid cystic carcinoma or acinic cell carcinoma) may lack significant contrast enhancement, leading to oversight or underestimation of the lesion [2].
In total, the evaluation included 9 studies on malignant salivary gland tumors and 22 on benign and malignant. In most studies, pleomorphic adenoma was most likely in benign tumors in approximately 42% of cases [21], [28]. The three prevalent malignant salivary gland tumors are adenoid cystic carcinoma, mucoepidermoid carcinoma and acinic cell carcinoma [29]. The distribution of tumor types broken down by countries is shown in Table 2. Irregular margins, bony invasions, the presence of metastatic lymph nodes and perineural spread can all be signs of malignancy [30]. Necrosis can also characterize malignancy [31].

### Tumor type

**Distribution of malignant salivary gland tumors**

Examining all salivary gland tumors, the distribution of malignant and benign also differed, as shown in Table 3. The distribution also differed for minor and major salivary gland tumors. In Brazil, only 20% of all tumors were malignant [32], whereas this number was much higher in Nigeria, where 71.1% were diagnosed [19]. We found no reliable studies or reviews from Germany because most of the data were from limited patient groups or were not properly itemized.

---

| Country   | Malignant tumors | Source |
|-----------|------------------|--------|
|           | adenoid cystic   | [8],   |
|           | carcinoma        | [37]   |
|           | mucoepidermoid   |        |
|           | carcinoma        |        |
|           | acinic cell      |        |
|           | carcinoma        |        |
| USA       | 71.0%            | 12–17% |
| China     | 32.9%            |        |
| Germany   | 32.6%            |        |
| Finland   | 27.0%            |        |
| Denmark   | 25.2%            |        |
| India     | 25.0%            |        |
| Brazil    | 20.0%            |        |
| Nigeria   | 20.0%            |        |
| Serbia    | 13.6%            |        |
| Sri Lanka | 13.5%            |        |
| Canada    | 9.3%             |        |
| Israel    | 6.3%             |        |
| Italy     | –*               |        |
| Turkey    | –*               |        |
| Korea     | –*               |        |
| Spain     | –*               |        |
| England   | –*               |        |

* no available information
Histologic entities of salivary gland tumors

It has been difficult to categorize salivary gland tumors according to their clinical behavior. To retain the kind of tumors, Schwenzer/Grimm and Barnes published a differentiated WHO histological classification of tumors of salivary glands in 1981 [33] and in 2005 [34] (Table 4).

Therapeutic aspects of salivary gland tumors

Salivary gland carcinomas are tumors with a heterogeneous morphology that require distinctive surgical therapy [2]. Surgical excision is the treatment of choice for resectable tumors [2]. Chemotherapy for salivary gland tumors can be ineffective. Studies of newly targeted therapies have not offered significant benefits [35]. Successes with chemotherapy alone and/or combinations with radiotherapy have been recorded for salivary duct carcinoma and carcinoma ex pleomorphic adenoma [36]. Histologic grade is important for prognosis and therapy. Surgery remains the mainstay of treatment when negative margins can be achieved. Radiation improves locoregional control of tumors with high-risk features [35]. In conclusion, more additive prognostic parameters are of great interest. This individual molecular signaling is further discussed in detail.

Discussion

With the aforementioned key words and generally available research mechanisms, e.g., PubMed.gov, more than 37,000 publications could be identified. At first glance, this seems to represent a unique treasure trove of data. However, applicable and valuable data were extracted by careful categorization and selection, which is necessary because articles that present a current overview of benign and malignant salivary gland tumors are missing. Despite differing countries of origin, our work identified several similarities. For example, benign tumors were more common than malignant ones. The prevalent benign tumor was PA, and the prevalent malignant tumors were ACC and MEC [5], [6]. The majority of tumors in the minor salivary glands and in the sublingual gland were malignant [7], [11].

The significance of the evaluated literature is indicated, but it differs for every country and every tumor entity. In some countries, the studies include thousands of patients, whereas in other countries, the studies include only up to a few hundred patients. The studies are often of one single institute and do not evaluate the whole country. Tumor research also differs. Most research concerns the most prevalent tumors (e.g., PA), but more attention should be focused on malignant ones because a permanent and frequently extended overview about therapy, prognosis and the distribution of different features (e.g., gender, age, proportion of malign and benign) is currently needed for improved diagnosis and treatment in the future. This could also provide insights into the formulation of risk groups to receive recurring preventive examinations. In all reviewed publications, however, none showed a correlation with cultural standings, living circumstances or habits (e.g., smoking, alcoholism).

To the best of our knowledge, this is the largest research article of salivary gland tumors in terms of gender distribution. Moreover, this work primarily presents a scientific summary of the worldwide distribution of benign and malignant salivary gland tumors, their demographics, the distribution of multiple entities in the form of a mini review, as well as the clinical features (e.g., symptoms, therapy, prognosis) of general salivary gland tumors. To our knowledge, this is the first article to contain all of these characteristics, thus providing a specific view perspective.

By comparing these results with squamous cell carcinoma (SCC) of the oral cavity, for which such questions have been undergoing assessments with great success for almost two decades, the research activity for malignant salivary gland tumors is in its infancy. This article reveals an apparent lack of research in Germany. A thorough analysis from a maxillofacial surgical standpoint is also missing. A next step will thus be to perform a monocentric study of this topic, particularly because prognostic assertions of benign and malignant forms (PA, ACC, MEC, AcCC) will be of great clinical importance. The University of Halle (Saale) is currently evaluating its diagnosed tumor entities over the last 25 years to provide this missing information. However, the results must be combined with other university findings to generate a holistic view of different tumor entities in Germany.

### Table 3: The different occurrences of minor and major salivary gland tumors worldwide

| Country      | Proportion benign : malignant tumors | Source |
|--------------|--------------------------------------|--------|
| Brazil       | 80.0% : 20.0%                        | [32]   |
| Serbia       | 73.4% : 26.6%                        | [6]    |
| Mexico       | 67.0% : 23.0%                        | [51]   |
| Croatia      | 64.2% : 35.8%                        | [24]   |
| India        | 62.0% : 38.0%                        | [43]   |
| Pakistan     | 58.2% : 41.8%                        | [5]    |
| Sri Lanka    | 49.9% : 50.1%                        | [44]   |
| Nigeria      | 28.9% : 71.1%                        | [19]   |
| 
| Minor salivary gland tumors | |
| Israel       | 59.0% : 41.0%                        | [28]   |
| USA          | 57.5% : 42.5%                        | [26]   |
| Iran         | 53.7% : 46.3%                        | [22]   |
| China        | 43.1% : 56.9%                        | [38]   |
| Libya        | 38.6% : 61.3%                        | [9]    |
### Table 4: WHO detailed classification of salivary gland tumors (according to Schwenzer/Grimm and Barnes)

**WHO histological classification of the tumors of salivary glands**

**Schwenzer and Grimm, 1981 [33]**

I. Growth originating from glandular tissue (Sialome)

1. benign with no or low relapse tendency
   - a.) monomorph adenoma
   - b.) adenolymphoma

2. benign with high relapse tendency
   - c.) mixed tumor (pleomorph adenoma)

3. malignant with low malignancy
   - d.) mucoepidermoid carcinoma
   - e.) acinic cell carcinoma
   - f.) adenoid cystic carcinoma

4. malignant with high malignancy
   - g.) salivary gland carcinoma

II. Growth originating from interstitial gland tissue (Symsialome)

1. benign:
   - h.) angioma (hemangioma, lymphangioma)
   - i.) neurinoma and neurofibroma
   - j.) lipoma

2. malignant:
   - k.) sarcoma
   - l.) lymphoreticular tumor

**Barnes et al, 2005 [34]**

I. Malignant epithelial tumors

- a.) Acinic cell carcinoma 8550/3
- b.) Mucoepidermoid carcinoma 8430/3
- c.) Adenoid cystic carcinoma 8200/3
- d.) Polymorphous low-grade adenocarcinoma 8525/3
- e.) Epithelial-myoepithelial carcinoma 8562/3
- f.) Clear cell carcinoma, not otherwise specified 8310/3
- g.) Basal cell adenocarcinoma 8147/3
- h.) Sebaceous carcinoma 8410/3
- i.) Sebaceous lymphadenocarcinoma 8410/3
- j.) Cystadenocarcinoma 8440/3
- k.) Low-grade cribriform cystadenocarcinoma

II. Benign epithelial tumors

- l.) Mucinous adenocarcinoma 8480/3
- m.) Oncocytic carcinoma 8290/3
- n.) Salivary duct carcinoma 8500/3
- o.) Adenocarcinoma, not otherwise specified 8140/3
- p.) Myoepithelial carcinoma 8982/3
- q.) Carcinoma ex pleomorphic adenoma 8941/3
- r.) Carcinosarcoma 8980/3
- s.) Metastasizing pleomorphic adenoma 8940/1
- t.) Squamous cell carcinoma 8070/3
- u.) Small cell carcinoma 8041/3
- v.) Large cell carcinoma 8012/3
- w.) Lymphoepithelial carcinoma 8082/3
- x.) Sialoblastoma 8974/1

III. Soft tissue tumors

- y.) Pleomorphic adenoma 8940/0
- z.) Myoepithelioma 8982/0
- aa.) Basal cell adenoma 8147/0
- bb.) Warthin tumor 8561/0
- cc.) Oncocytoma 8290/0
- dd.) Canalicular adenoma 8149/0
- ee.) Sebaceous adenoma 8410/0

ff.) Lymphadenoma
   - Sebaceous 8410/0
   - Non-sebaceous 8410/0

gg.) Ductal papillomas
   - Inverted ductal papilloma 8503/0
   - Intraductal papilloma 8503/0
   - Sialadenoma papilliferum 8406/0

hh.) Cystadenoma 8440/0

IV. Hematolymphoid tumors

- ii.) Hodgkin lymphoma

jj.) Diffuse large B-cell lymphoma 9698/3

kk.) Extramedullary marginal zone B-cell lymphoma 9699/3

V. Secondary tumors

Morbidity code of the International Classification of Disease for Oncology (ICD-0) (821) and the Systematized Nomenclature of Medicine (http://snomed.org)

Behavior is coded /0 for benign tumors, /3 for malignant tumors, and /1 for borderline or uncertain behavior
Notes

Acknowledgements

We thank our colleagues from the Department of Oral and Maxillofacial Plastic Surgery for contributing to this study and for their continuous support.

Competing interests

The authors declare that they have no competing interests.

References

1. Lawal AO, Adisa AO, Kolude B, Adeyemi BF. Malignant salivary gland tumours of the head and neck region: a single institutions review. Pan Afr Med J. 2015 Feb 12;20:121. DOI: 10.11604/pamj.2015.20.121.3458
2. Ett T, Schwarz-Furlan S, Gosau M, Reichert TE. Salivary gland carcinomas. Oral Maxillofac Surg. 2012 Sep;16(3):267-83. DOI: 10.1007/s10006-012-0350-9
3. Bradley PJ. Primary malignant parotid epithelial neoplasm: nodal metastasises and management. Curr Opin Otolaryngol Head Neck Surg. 2015 Apr;23(2):91-8. DOI: 10.1097/MOO.0000000000000139
4. Dahl A, Teegen J, Attevogt P, Lönig T, Schumacher U. Glycoconjugate expression in adenoid cystic carcinoma of the salivary glands: up-regulation of L1 predicts fatal prognosis. Histopathology. 2011 Aug;59(2):299-307. DOI: 10.1111/j.1365-2559.2011.03895.x
5. Zaman S, Majid S, Chugtai O, Hussain M, Nasir M. Salivary gland tumours in a Nigerian hospital: a retrospective review of the literature. Acta Neurochir (Wien). 2017 Mar;159(3):459-63. DOI: 10.1007/s00701-017-3080-9.
6. Moatemri R, Belajouza H, Farroukh U, Ommezzine M, Slama A, Ayachi S, Khochtali H, Bakir A. [Epidemiological profile of salivary-glands tumours in a Tunisian teaching hospital]. Rev Statomato Chir Maxillofac. 2008 Jun;109(3):148-52. DOI: 10.1016/j.revmoto.2008.04.001
7. Jonker A, Vossen H, Kool M, Van der Meulen C. [The 1997-2010 period, 10 years of experience from a single institution in Croatia]. J Craniomaxillofac Surg. 2012 Apr;40(3):e75-81. DOI: 10.1016/j.jcms.2011.05.002
8. Jonker A, Vossen H, Kool M, Van der Meulen C. [The 1997-2010 period, 10 years of experience from a single institution in Croatia]. J Craniomaxillofac Surg. 2012 Apr;40(3):e75-81. DOI: 10.1016/j.jcms.2011.05.002
9. Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA. Salivary gland tumours in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg. 2005 Mar;34(3):235-42. DOI: 10.1016/j.ijom.2004.10.016
10. Moameni R, Belajouza H, Farroukh U, Ommezzine M, Slama A, Ayachi S, Khochtali H, Bakir A. [Epidemiological profile of salivary-glands tumours in a Tunisian teaching hospital]. Rev Statomato Chir Maxillofac. 2008 Jun;109(3):148-52. DOI: 10.1016/j.revmoto.2008.04.001
11. Jonker A, Vossen H, Kool M, Van der Meulen C. [The 1997-2010 period, 10 years of experience from a single institution in Croatia]. J Craniomaxillofac Surg. 2012 Apr;40(3):e75-81. DOI: 10.1016/j.jcms.2011.05.002
12. Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA. Salivary gland tumours in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg. 2005 Mar;34(3):235-42. DOI: 10.1016/j.ijom.2004.10.016
13. Abu-Ghanem Y, Mizrachi A, Popovtzer A, Abu-Ghanem N, Feinmesser R. Recurrent pleomorphic adenoma of the parotid gland: Institutional experience and review of the literature. J Surg Oncol. 2016 Nov;114(6):714-8. DOI: 10.1002/jso.24392
14. Knight J, Ratnasingham K. Metastasising pleomorphic adenoma: Systematic review. Int J Surg. 2015 Jul;19:137-45. DOI: 10.1016/j.ijsu.2015.04.084
15. Gondivkar SM, Gadball AR, Chole R, Parikh RV. Adenoid cystic carcinoma: a rare clinical entity and literature review. Oral Oncol. 2011 Apr;47(4):231-6. DOI: 10.1016/j.oraloncology.2011.01.009
16. Sur RK, Donde B, Levin V, Pacella J, Kotzen J, Cooper K, Hale M. Adenoid cystic carcinoma of the salivary glands: a review of 10 years. Laryngoscope. 1997 Sep;107(9):1278-80. DOI: 10.1097/00005537-199709000-00022
17. Chundru NS, Amudaia R, Thanikappan P, Nagaraju CD. Adenoid cystic carcinoma of palate: A case report and review of literature. Dent Res J (Isfahan). 2013 Mar;10(2):274-8.
18. Rapidis AD, Givalos N, Gakipoulou H, Stavrianos SD, Faratzis G, Lagogiannis GA, Katsiliiera I, Patsouris E. Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. Oral Oncol. 2007 Feb;43(2):130-6. Epub 2006 Jul 20. DOI: 10.1016/j.oraloncology.2006.03.001
19. Fomete B, Adebayo ET, Ononiuw CN. Management of salivary gland tumours in a Nigerian tertiary institution. Ann Afr Med. 2015 Jul-Sep;14(3):148-54. DOI: 10.4103/1596-3519.152071
20. Moamenti R, Belajouza H, Farroukh U, Ommezzine M, Slama A, Ayachi S, Khochtali H, Bakir A. [Epidemiological profile of salivary-glands tumours in a Tunisian teaching hospital]. Rev Statomato Chir Maxillofac. 2008 Jun;109(3):148-52. DOI: 10.1016/j.revmoto.2008.04.001
21. Adebji KE, Emmanuel MM. Neoplastic Salivary Gland Lesions: A Retrospective Analysis of 135 Cases from Lagos State University Teaching Hospital, Ijek, Lagos, Nigeria. West Afr J Med. 2014 Jul-Sep;33(3):206-10.
22. Jaafar-Ashkavandi Z, Ashraf MJ, Afandak N. A clinicopathologic study of 82 intraoral minor salivary gland tumors. Iran Red Crescent Med J. 2011 Sep;13(9):674-7.
23. Tian Z, Li L, Wang L, Hu Y, Li J. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg. 2010 Mar;39(3):235-42. DOI: 10.1016/j.ijom.2009.10.016
24. Lukšić I, Virag M, Manojlović S, Macan D. Salivary gland tumours: 25 years of experience from a single institution in Croatia. J Craniomaxillofac Surg. 2012 Apr;40(3):e75-81. DOI: 10.1016/j.jcms.2011.05.002
25. Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA. Salivary gland tumours in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg. 2005 Jul;34(5):533-6. DOI: 10.1016/j.ijom.2005.07.006
26. Waldron CA, el-Mofty SK, Gnepp DR. Tumors of the intraoral minor salivary glands: a demographic and histologic study of 426 cases. Oral Surg Oral Med Oral Pathol. 1988 Sep;66(3):323-33. DOI: 10.1016/0030-4220(88)90240-X
27. Razfar A, Heron DE, Cranston BF 4th, Seethala RR, Ferris RL. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope. 2010 Apr;120(4):734-8. DOI: 10.1002/1.20829
28. Buchner A, Morrell PW, Carpenter WM. Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. J Oral Pathol Med. 2007 Apr;36(4):207-14. DOI: 10.1111/j.1600-0714.2007.00522.x
29. Márgáritescu C, Munteanu MC, Nitulescu NC, Conca L, Cotoi OS, Paskova G. Acinic cell carcinoma of the salivary glands: an immunohistochimical study of angiogenesis in 12 cases. Rom J Morphol Embryol. 2013;54(2):275-84.

30. Wierzbicka M, Kopeć T, Szyfter W, Kereiakes T, Babu NG. Acinic cell carcinoma of the salivary glands: a single institution experience. Cancer. 2005 Jun;104(6):1177-82. DOI: 10.1002/cncr.21248

31. Zbären P, Schüpbach J, Nuyens M, Stauffer E, Greiner R, Häusler R. Carcinoma of the parotid gland. Am J Surg. 2003 Jul;186(1):57-62. DOI: 10.1016/S0002-9610(03)00105-3

32. Vargas PA, Gerhard R, Araújo Filho VJ, de Castro IV. Salivary gland tumors in a Brazilian population: a retrospective study of 124 cases. Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):271-6. DOI: 10.1590/S0041-87812002000600005

33. Schwenzer N, Grimm G. Allgemeine Chirurgie, Entzündungen und Röntgenologie. 1. Aufl., rev. Nachdr. [S.l.]: [s.n.]; 1981. (Zahn-Mund-Kiefer-Heilkunde; 1).

34. Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization Classification of Tumours. Pathology and genetics of head and neck tumours. Lyon: IARCPress; 2005. World Health Organization Classification of tumours; 9.

35. Lewis AG, Tong T, Maghami E. Diagnosis and Management of Malignant Salivary Gland Tumors of the Parotid Gland. Otolaryngol Clin North Am. 2016 Apr;49(2):343-80. DOI: 10.1016/j.clonc.2015.11.003

36. Lewis AG, Tong T, Maghami E. Diagnosis and Management of Malignant Salivary Gland Tumors of the Parotid Gland. Otolaryngol Clin North Am. 2016 Apr;49(2):343-80. DOI: 10.1016/j.otc.2015.04.001

37. Garden AS, Webers RS, Ang KK, Morrison WH, Matre J, Peters LJ. Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer. 1994 May 15;73(10):2563-9.

38. Li YN, He XZ, Liu LK, He HW. [A retrospective study on 615 cases of minor salivary gland tumors]. Hua Xi Kou Qiang Yi Xue Za Zhi. 2004 Jun;22(3):204-6.

39. Hessling JT. Eine retrospektive Analyse von 18 Jahren aus der Klinik und Poliklinik für Mund-, Kiefer- und plastische Gesichtschirurgie der Universität Bonn im Vergleich zur aktuellen Klinik und Poliklinik für Mund-, Kiefer- und plastische Gesichtschirurgie. 4., vollst. überarb. u. erw. Aufl. Stuttgart, New York: Thieme; 2010. (Zahn-Mund-Kiefer-Heilkunde; 1).

40. Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, Virtanen M, Paskova G. Acinic cell carcinoma of the salivary glands: an unusual presentation. J Cancer Res Ther. 2015 Oct-Dec;11(4):1931-3. DOI: 10.4103/0973-1482.157352

41. Bjernadal K, Krogdahl A, Therikilden MH, Overgaard J, Johansen J, Kristensen CA, Homée P, Sørensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C. Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2011 Jul;47(7):677-82. DOI: 10.1016/j.joraloncol.2011.04.020

42. Aravind RM, Narayanan NS, Ravishankar KS, Babu NG. Acinic cell carcinoma of buccal mucosa: An unusual presentation. J Cancer Res Ther. 2015 Oct-Dec;11(4):1931-3. DOI: 10.4103/0973-1482.157352

43. Subhashraj K. Salivary gland tumors: a single institution experience in India. Br J Oral Maxillofac Surg. 2008 Dec;46(8):635-8. DOI: 10.1016/j.bjoms.2008.03.020

44. Erovic BM, Shah MD, Bruch G, Johnston M, Kim J, O’Sullivan B, Perez-Ordonez B, Weinreb I, Atanu EN, De Almeida JR, Gullane PJ, Brown D, Gilbert RW, Irish JC, Goldstein DP. Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. J Otolaryngol Head Neck Surg. 2015 Oct 29;44(4). DOI: 10.1186/s40463-015-0097-z

45. Mesolella M, Iengo M, Testa D, Di Lullo AM, Salzano G, Salzano FA. Mucoepidermoid carcinoma of the base of tongue. Acta Otorhinolaryngol Ital. 2015 Feb;35(1):58-61.

46. Attinà S, Taskun U, Sar M, Aydin S, Oktay MF. Histopathological diversity in parotidectomy materials in Turkish population: clinicopathologic analysis and demographic features of 136 cases in a tertiary care hospital. Asian Pac J Cancer Prev. 2014;15(14):5701-7. DOI: 10.7314/APJCIP.2014.15.14.5701

47. Cha W, Kim MS, Ahn JC, Cho SW, Sunwoo W, Song CM, Kwon TK, Sung MW, Kim KH. Clinical analysis of acinic cell carcinoma in parotid gland. Clin Exp Otorhinolaryngol. 2011 Dec;4(4):188-92. DOI: 10.3342/ceo.2011.4.4.188

48. Rosero DS, Alvarez R, Gambó P, Alastuey M, Valero A, Torrecilla N, Roche AB, Simón S. Acinic Cell Carcinoma of the Parotid Gland with Four Morphological Features. Iran J Pathol. 2016 Spring;11(2):181-5.

49. Tuffin JR, Daniel F, Davies AS, Tyrrell CJ. Acinic cell carcinoma – Plymouth’s experience with postoperative radical radiotherapy. Br J Oral Maxillofac Surg. 1989 Jun;27(3):186-91. DOI: 10.1016/0002-9610(89)90142-3

50. Mejía-Velázquez CP, Durán-Padilla MA, Gómez-Apo E, Quezada-Rivera D, Gaitán-Cepeda LA. Tumors of the salivary gland in Mexicans. A retrospective study of 360 cases. Med Oral Patol Cir Bucal. 2012 Mar 1;17(2):e183-9. DOI: 10.4317/medoral.17434

Corresponding author:
Theresa Marie Galdirs
Martin Luther University Halle-Wittenberg, University hospital, Department of Oral and Maxillofacial Plastic Surgery, Ernst-Grube-Str. 40, 06120 Halle/Saale, Germany, Phone: +49 345 557 5246, Fax: +49 345 557 5291
Theresa_Galdirs@gmx.de

Please cite as
Galdirs TM, Kappler M, Reich W, Eckert AW. Current aspects of salivary gland tumors – a systematic review of the literature. GMS Interdiscipl Plast Reconstr Surg DGPW. 2019;8:Doc12. DOI: 10.3205/iprs000138, URN: urn:nbn:de:0183-iprs0001381

This article is freely available from
https://www.gms.de/en/journals/iprs/2019-8/ips000138.shtml

Published: 2019-08-02

Copyright ©2019 Galdirs et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.